The ICH Q5A Revision, Its New Scope And Guidance
Source: MilliporeSigma
The ICH Q5A revision addressing viral safety of biotechnology products derived from cell lines of human or animal origin was recently published for public comment.
In addition to therapeutic proteins and plasma products, genetically engineered viral vectors and viral vector-derived products are in scope. This is only if viral clearance methods do not have a negative impact on the quality of the product. Specific guidance on these products is also included.
access the Video!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.
Subscribe to Bioprocess Online
X
Subscribe to Bioprocess Online
MilliporeSigma
This website uses cookies to ensure you get the best experience on our website. Learn more